P&MA Assessment to Support BD&L Decision-Making

Home / Intelligence / Case Studies / P&MA Assessment to Support BD&L Decision-Making

Trinity completed a P&MA assessment for a gene therapy in Leber hereditary optic neuropathy (LHON) to support BD&L decision-making.

Geographic Scope:

Client Situation

The client wanted to understand the current and future market landscape and the resulting pricing and access potential for a gene therapy asset in Leber hereditary optic neuropathy to support their BD&L decision-making.

Trinity’s Solution

Trinity conducted in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practices and price thresholds for LHON, and understand likely payer restrictions as a function of price.

Deliverables

Landscape assessment and analogue assessment across key markets
Payer & KOL moderator guides and research stimuli
Interim research findings summary
Detailed final research findings summary
Strategic business development and licensing (BD&L) recommendations and differentiation opportunities

Project Outcomes & Impact

The strategic guidance that Trinity delivered informed the client’s decision not to move forward with the acquisition of the LHON gene therapy asset.

Related Intelligence

Webinars

Annual State of Global Market Access Webinar

Available On Demand

Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the […]

Watch Now

White Papers

Annual State of Global Market Access

In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]

Blog

Cell and Gene Therapies: Six Global Trends We Are Watching in 2024

2023 was a busy year for cell and gene therapies (C&GT). There were regulatory approvals in the U.S. and EU, including both in rare pediatric conditions with no current effective options (e.g., Duchenne muscular dystrophy (DMD)), as well as in indications where competition is better established (e.g., hemophilia A and B). Towards the end of […]